Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group.
about
Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgeryImmune tolerance induction for treating inhibitors in people with congenital haemophilia A or BTreatment for preventing bleeding in people with congenital bleeding disorders undergoing surgeryImmune tolerance induction for treating inhibitors in people with congenital haemophilia A or BEstimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxisAlloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicityClinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentratesHemophilia A gene therapy via intraosseous delivery of factor VIII-lentiviral vectorsHaemophilia management: time to get personal?Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXThe social burden and quality of life of patients with haemophilia in Italy.Current and evolving features in the clinical management of haemophiliaThe cost of severe haemophilia in Europe: the CHESS study.Haemophilia utilization group study - Part Va (HUGS Va): design, methods and baseline data.Physical and psychosocial challenges in adult hemophilia patients with inhibitors.The economics of inpatient on-demand treatment for haemophilia with high-responding inhibitors: a US retrospective data analysis.Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practicePrinciples of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyContent comparison of haemophilia specific patient-rated outcome measures with the international classification of functioning, disability and health (ICF, ICF-CY).Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIIIDesigned ankyrin repeat proteins: a new approach to mimic complex antigens for diagnostic purposes?A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia AIntraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A.Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in IranTreatment of hemophilia: a review of current advances and ongoing issuesA role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytesDisease-specific quality-of-life measurement tools for haemophilia patients.Inhibitors in congenital coagulation disorders.Therapy for haemophilia: recent advances and goals for the future.The Utilization of Rehabilitation in Patients with Hemophilia A in Taiwan: A Nationwide Population-Based Study.Addressing current challenges in haemophilia care: consensus recommendations of a European Interdisciplinary Working Group.Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study.Health economics of treating haemophilia A with inhibitors.Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors.Quality of life assessment in clinical practice in haemophilia treatment.Economic burden of high-responding inhibitors in patients with hemophilia A in Taiwan.Prophylaxis in haemophilia patients with inhibitors.Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors.International workshop on immune tolerance induction: consensus recommendations.
P2860
Q24188177-A618133A-14B6-4827-AA28-CF87C6A4C125Q24195006-2B70A963-8B01-4184-AAF9-91A0B0ECFD13Q24202459-BF071278-BA75-4111-B7F1-0BB37B38CDBAQ24202592-EBFEF893-4C1C-497E-B34C-57641EEFA340Q26865814-78C192D5-9E3E-46EC-B46E-301684BBB7CAQ26866323-620E4189-26D4-49A5-8D16-5F26E0A15B00Q27026389-FBCDEF27-7B91-47AA-9D0D-00C38C22B287Q28079890-14C39793-086A-4397-9296-D4F3B35DBD40Q30403530-AE7C5FCD-0429-41EB-B782-4E2B754FCDC1Q33608230-29A89EB8-1D24-4E4D-A8A9-1B0086E0D9EEQ33708947-E31548F7-DA0C-4123-8DEC-CB2B073749D0Q33708976-3F6C5063-46A7-4AB9-A658-018A5EEADAE0Q33750095-A8E4C7CC-178F-441B-9379-B13EB6D9F4FBQ33937275-DE659BE8-7B58-48A9-89F9-D115BABCD7CCQ33968730-AFBFE875-5022-4278-8719-31CF40E04F08Q33980524-4C3C5290-8780-45ED-80AB-B5A19B14CF09Q34157402-42926062-7C59-4CF2-BC7D-788534E0AC9DQ34416394-48624E61-0452-4F49-9733-EFF4C7E38693Q34498533-5D0544D1-F680-490E-9751-121A125355A9Q34550081-59EF478F-F059-4983-AC7D-F162482735AAQ34692067-BA83B4A3-F75A-41B9-89B8-B1049577D88FQ35176160-18FA2B40-2431-4790-874B-3363A01BB6BAQ35205428-18106860-B77A-4EB4-9CA7-35F352F35B5EQ35399235-20584907-B274-4919-9DE1-FD1EFC1824F3Q35602600-B9BE9340-85C8-4220-85E2-2D13F3119A74Q35683781-A9AF6381-432E-4093-8B1B-EF30DB295F54Q35829158-A5AAE414-C2B7-4229-B722-5D714B3EDA53Q35915643-8CD299A4-D628-4B26-9DFF-13B88DC82BA4Q35937076-C36EC9B0-61E4-4D12-AA11-E96F3CE74F07Q36066048-F86C3665-76CA-4D1D-B7B2-F6B7D16A8490Q36149893-7675A5C6-EE22-4F0D-94CC-C767F23ADB95Q36243457-D6C599DB-9B2D-4F0C-B567-0F02B91891EDQ36244249-F2B325C2-4258-4F1E-834F-0C72625663FBQ36283841-370FC951-7622-4989-A96A-6BE061B21B32Q36291064-81C7F64A-B18D-4EC3-9552-A8787AE856DBQ36473028-CE27503E-B835-4EA6-8794-2E218504699FQ36620369-F6A83E75-4BBA-48F2-AE22-C0ACC6397445Q36661844-48BCCA33-42ED-4DED-BDE1-D89DB6F9B79BQ36828144-08B82E67-FB3C-49C8-AE8E-C75B092E770BQ36861097-FD3BFB38-DCC8-4DE6-B3A8-E50B26C4A44F
P2860
Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Cost of care and quality of li ...... bitors: the COCIS Study Group.
@en
Cost of care and quality of li ...... bitors: the COCIS Study Group.
@nl
type
label
Cost of care and quality of li ...... bitors: the COCIS Study Group.
@en
Cost of care and quality of li ...... bitors: the COCIS Study Group.
@nl
prefLabel
Cost of care and quality of li ...... bitors: the COCIS Study Group.
@en
Cost of care and quality of li ...... bitors: the COCIS Study Group.
@nl
P2093
P921
P1433
P1476
Cost of care and quality of li ...... bitors: the COCIS Study Group.
@en
P2093
Alessandro Gringeri
COCIS Study Group
Luciana Scalone
P304
P356
10.1182/BLOOD-2003-03-0941
P407
P577
2003-06-19T00:00:00Z